2 research outputs found

    Cost effectiveness acceptability curves for vaccination of girls aged 12 years with a quadrivalent vaccine at different levels of three dose coverage, for different assumptions about duration of protection from vaccine

    No full text
    Incremental cost effectiveness of vaccination compared with no vaccination option is shown. Region of £20 000-£30 000 per QALY gained is shaded<p><b>Copyright information:</b></p><p>Taken from "Economic evaluation of human papillomavirus vaccination in the United Kingdom"</p><p></p><p>BMJ : British Medical Journal 2008;337():-.</p><p>Published online 31 Jul 2008</p><p>PMCID:PMC2500202.</p><p></p

    Cost effectiveness acceptability curves for base case vaccination programme (girls aged 12 years only, quadrivalent vaccine, 80% coverage) under different assumptions about duration of protection from vaccine

    No full text
    Incremental cost effectiveness of vaccination compared with no vaccination option is shown. Region of £20 000- £30 000 per QALY gained is shaded. Thick solid and dashed lines indicate cost effectiveness acceptability curves when considering vaccine type cervical cancers in a screened population, medium solid and dashed lines indicate curves assuming 80% coverage in screened and unscreened populations, and thin solid and dashed lines indicate curves assuming 80% coverage in screened and unscreened populations, protection against non-cervical cancers, and some cross protection against non-vaccine types<p><b>Copyright information:</b></p><p>Taken from "Economic evaluation of human papillomavirus vaccination in the United Kingdom"</p><p></p><p>BMJ : British Medical Journal 2008;337():-.</p><p>Published online 31 Jul 2008</p><p>PMCID:PMC2500202.</p><p></p
    corecore